In The Claims:

Please amend claims 56 and 95 as follows:

56. (Twice Amended) A method of combating a viral infection in a subject in need of such treatment, wherein the viral infection comprises a virus selected from the group consisting of HIV-1, HBV, herpes virus, influenza, respiratory syncytial virus, mumps, measles, and parainfluenza virus, the method comprising administering to said subject an effective infection-combating amount of a compound of Formula III



(III)

wherein: R_1 is a branched or unbranched, saturated or unsaturated C_6 to C_{18} alkyl group optionally substituted from 1 to 5 times with -OH, -COOH, oxo, amine, or substituted or unsubstituted aromatic;

X is selected from the group consisting of NHCO, CH_3NCO, CONH, $CONCH_3$, S, SO, SO_2, O, NH, and NCH_3;

R_2 is a branched or unbranched, saturated or unsaturated C_6 to C_{14} alkyl group optionally substituted from 1 to 5 times with -OH, -COOH, oxo, amine, or substituted or unsubstituted aromatic;

Y is selected from the group consisting of NHCO, CH_3NCO, CONH, $CONCH_3$, S, SO, SO_2, O, NH, and NCH_3; and

Z is a moiety of the Formula V,



, (V)

wherein: V is H or N_3;

W is H or F; or

V and W together are a covalent bond; and

B is a purinyl moiety of Formula VI



(VI)

optionally substituted at position 2 with -OH, -SH, $-NH_2$ or halogen, at position 6 with Cl, $-NH_2$, -OH, or C_1-C_3 alkyl, and at position 8 with Br or I; or

B is a pyrimidinyl moiety of Formula VII



(VII)

substituted at position 4 with =O or NH_2 and optionally substituted at position 5 with halogen or C_1-C_3 saturated or unsaturated alkyl optionally substituted 1 to 3 times with halogen;

or a pharmaceutical salt thereof.

95. (Twice Amended) A compound of Formula III



(III)

wherein: R_1 is a branched or unbranched, saturated or unsaturated C_6 to C_{18} alkyl group optionally substituted from 1 to 5 times with -OH, -COOH, oxo, amine, or substituted or unsubstituted aromatic;

X is selected from the group consisting of NHCO, CH_3NCO, CONH, $CONCH_3$, S, SO, SO_2, O, NH, and NCH_3;

R_2 is a branched or unbranched, saturated or unsaturated C_6 to C_{14} alkyl group optionally substituted from 1 to 5 times with -OH, -COOH, oxo, amine, or substituted or unsubstituted aromatic;

Y is selected from the group consisting of NHCO, CH_3NCO, CONH, $CONCH_3$, S, SO, SO_2, O, NH, and NCH_3; and

Z is a moiety of the Formula V,



, (V)

wherein: V is H or N_3;

W is H or F; or

V and W together are a covalent bond; and

B is a purinyl moiety of Formula VI



(VI)

optionally substituted at position 2 with -OH, -SH, $-NH_2$ or halogen, at position 6 with Cl, $-NH_2$, -OH, or C_1-C_3 alkyl, and at position 8 with Br or I; or

B is a pyrimidinyl moiety of Formula VII



(VII)

substituted at position 4 with =O or NH_2 and optionally substituted at position 5 with halogen or C_1-C_3 saturated or unsaturated alkyl optionally substituted 1 to 3 times with halogen.

Please delete claim 101 without prejudice to the presentation of this claim in any subsequently filed divisional or continuation application.

Please add new claims 103-109 as follows:

103. (New) The method of claim 56 wherein R_1 is $(CH_2)_{10}$ CH_3.

104. (New) The method of claim 56 wherein R_2 is $(CH_2)_7$ CH_3.

105. (New) The method of claim 56 wherein X is NHCO.

106. (New) The method of claim 56 wherein:

R_1 is $(CH_2)_{10}$ CH_3;

X is NHCO;

R_2 is $(CH_2)_7$ CH_3; and

Y is O.

107. (New) The method of claim 56 wherein:

V is N_3;

W is H; and

B is a pyrimidinyl moiety of Formula VII



(VII)

substituted at position 4 with =O and substituted at position 5 with CH_3.

108. (New) The compound of claim 95 wherein:

R_1 is $(CH_2)_{10}$ CH_3;

X is NHCO;

R_2 is $(CH_2)_7$ CH_3; and

Y is O.

109. (New) The compound of claim 95 wherein:

V is N_3;

W is H;

B is a pyrimidinyl moiety of Formula VII